{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T04:53:01Z","timestamp":1774414381330,"version":"3.50.1"},"reference-count":39,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s385094","type":"journal-article","created":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T12:20:08Z","timestamp":1673698808000},"page":"29-39","source":"Crossref","is-referenced-by-count":7,"title":["Elicitation of Health State Utility Values in Retinitis Pigmentosa by Time Trade-off in the United Kingdom"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Paul","family":"O'Brien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Enstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Wyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Banhazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-020-00281-y","volume":"5","author":"Lange","year":"2021","journal-title":"J Patient-Rep Outcomes"},{"key":"ref3","unstructured":"American Academy of Opthalmology. New treatments for retinitis pigmentosa; 2021. Available from: https:\/\/www.aao.org\/eye-health\/tips-prevention\/gene-therapy-new-retinitis-pigmentosa-lca-luxturna. Accessed December 28, 2022."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.21037\/atm-20-4747","volume":"9","author":"Ahmed","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.21037\/atm-20-4726","volume":"9","author":"Nuzbrokh","year":"2021","journal-title":"Ann Transl Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02546-9","volume":"12","author":"Hinkle","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"ref7","volume-title":"What Do We Know About Patients\u2019 and Caregivers\u2019 Experiences When Living with the Hereditary Retinal Condition Retinitis Pigmentosa?","year":"2019"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12325-021-02036-7","volume":"39","author":"Sallum","year":"2022","journal-title":"Adv Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/bjophthalmol-2018-313089","volume":"103","author":"Lloyd","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"ref11","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013\u20135 the reference case; 2013. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/the-reference-case. Accessed December 28, 2022."},{"key":"ref12","unstructured":"Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Canada; 2017. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf. Accessed December 28, 2022."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"ref14","volume-title":"Guidelines for Preparing a Submission to the Pharmaceutical Benefits Advisory Committee, Version 5.0","year":"2016"},{"key":"ref15","unstructured":"China Guidelines for Pharmacoeconomic Evaluations Working Group. China guidelines for pharmacoeconomic evaluations; 2020 Available from: https:\/\/tools.ispor.org\/PEguidelines\/source\/China-Guidelines-for-Pharmacoeconomic-Evaluations-2020.pdf. Accessed December 28, 2022."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"Shiroiwa","year":"2017","journal-title":"Value Health"},{"key":"ref17","unstructured":"National Institute for Health and Care Excellence. NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values. National Institute for Health and Care Excellence; 2011."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12913-018-2836-0","volume":"18","author":"Pezzullo","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s40273-016-0404-1","volume":"34","author":"Oppe","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"ref20","unstructured":"Nomis. Population estimates - local authority based by single year of age; 2018. Available from: https:\/\/www.nomisweb.co.uk\/livelinks\/13687.xlsx. Accessed December 28, 2022."},{"key":"ref21","unstructured":"Office for National Statistics. 2011 Census; 2011. Available from: https:\/\/www.ons.gov.uk\/census\/2011census. Accessed December 28, 2022."},{"key":"ref22","unstructured":"Office for National Statistics. Employment in the UK; 2019. Available from: https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/employmentandemployeetypes\/bulletins\/employmentintheuk\/december2019. Accessed December 28, 2022."},{"key":"ref23","unstructured":"Office for National Statistics. Highest level of qualification achieved by people living in UK regions, 2010 to 2018; 2019. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/educationandchildcare\/adhocs\/10516highestlevelofqualificationachievedbypeoplelivinginukregions2010to2018. Accessed December 28, 2022."},{"key":"ref24","unstructured":"Office for National Statistics. Population estimates by marital status and living arrangements, England and Wales; 2019. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesbymaritalstatusandlivingarrangements. Accessed December 28, 2022."},{"key":"ref25","unstructured":"Office for National Statistics. Population estimates for the UK, England and Wales, Scotland and Northern Ireland: mid-2018; 2019. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/latest. Accessed December 28, 2022."},{"key":"ref26","volume-title":"Self-Reported Population Health: An International Perspective Based on EQ-5D","year":"2014"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jval.2019.08.009","volume":"23","author":"Goodwin","year":"2020","journal-title":"Value Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-018-0897-8","volume":"16","author":"Castej\u00f3n","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1524-4733.2009.00527.x","volume":"12","author":"Czoski-Murray","year":"2009","journal-title":"Value Health"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1001\/jamaophthalmol.2013.7639","volume":"132","author":"Rentz","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0002-9394(99)00146-4","volume":"128","author":"Brown","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0161-6420(03)00254-9","volume":"110","author":"Brown","year":"2003","journal-title":"Ophthalmology"},{"key":"ref33","unstructured":"National Institute for Health and Care Excellence. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations; 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/hst11. Accessed December 28, 2022."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2017.01.014","volume":"176","author":"Na","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/eye.2016.315","volume":"31","author":"Prem Senthil","year":"2017","journal-title":"Eye"},{"key":"ref36","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choices in methods for economic evaluation; 2012. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2012-10\/choices_in_methods_for_economic_evaluation.pdf. Accessed December 28, 2022."},{"key":"ref37","unstructured":"Institute for Clinical and Economic Review. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value - final evidence report; 2018. Available from: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf. Accessed December 28, 2022."},{"key":"ref38","unstructured":"Tolley K What are health utilities? 2009. Available from: http:\/\/www.bandolier.org.uk\/painres\/download\/What%20is%202009\/What_are_health_util.pdf. Accessed December 28, 2022."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10198-017-0931-5","volume":"19","author":"Brazier","year":"2018","journal-title":"Eur J Health Econ"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=86836","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=86836","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T12:20:20Z","timestamp":1673698820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/elicitation-of-health-state-utility-values-in-retinitis-pigmentosa-by--peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":39,"URL":"https:\/\/doi.org\/10.2147\/ceor.s385094","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}